1,102
Views
42
CrossRef citations to date
0
Altmetric
Letter

Effective treatment of pomalidomide in central nervous system myelomatosis

, &
Pages 864-866 | Received 15 May 2012, Accepted 31 Jul 2012, Published online: 30 Aug 2012

References

  • Berenson JR, Yellin O, Cartmell AD, . A phase II study of pegylated liposomal doxorubicin (PLD), bortezomib, dexamethasone and lenalidomide (DVD-R) for patients with relapsed/refractory (R/R) multiple myeloma (MM). Blood 2010;116(Suppl. 1):Abstract 3044.
  • Varettoni M, Corso A, Pica G, . Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients. Ann Oncol 2010;21:325–330.
  • Gozzetti A, Cerase A, Lotti F, . Extramedullary intracranial localization of multiple myeloma and treatment with novel agents: a retrospective survey of 50 patients. Cancer 2012;118:1574–1184.
  • Chamberlain MC, Glantz M. Myelomatous meningitis. Cancer 2008;112:1562–1567.
  • Nieuwenhuizen L, Biesma DH. Central nervous system myelomatosis: review of the literature. Eur J Haematol 2008;80:1–9.
  • Petersen SL, Wagner A, Gimsing P. Cerebral and meningeal multiple myeloma after autologous stem cell transplantation. A case report and review of the literature. Am J Hematol 1999;62:228–233.
  • Fassas AB, Muwalla F, Berryman T, . Myeloma of the central nervous system: association with high-risk chromosomal abnormalities, plasmablastic morphology and extramedullary manifestations. Br J Haematol 2002;117:103–108.
  • Chang H, Sloan S, Li D, . Multiple myeloma involving central nervous system: high frequency of chromosome 17p13.1 (p53) deletions. Br J Haematol 2004;127:280–284.
  • Chang H, Bartlett ES, Patterson B, . The absence of CD56 on malignant plasma cells in the cerebrospinal fluid is the hallmark of multiple myeloma involving central nervous system. Br J Haematol 2005;129:539–541.
  • Patriarca F, Prosdocimo S, Tomadini V, . Efficacy of bortezomib therapy for extramedullary relapse of myeloma after autologous and non-myeloablative allogeneic transplantation. Haematologica 2005;90:278–279.
  • Muscal JA, Sun Y, Nuchtern JG, . Plasma and cerebrospinal fluid pharmacokinetics of thalidomide and lenalidomide in nonhuman primates. Cancer Chemother Pharmacol 2012;69:943–947.
  • Vicari P, Ribas C, Sampaio M, . Can thalidomide be effective to treat plasma cell leptomeningeal infiltration?Eur J Haematol 2003;70:198–199.
  • Lacy MQ, Rajkumar SV. Pomalidomide: a new IMiD with remarkable activity in both multiple myeloma and myelofibrosis. Am J Hematol 2009;85:95–96.
  • Moghadddam M, Katz J, Tang Y. Brain microdialysis of pomalidomide in rats. Presented at the 17th North American Regional ISSX Meeting. October 2011. Atlanta, GA. Abstract #P91.
  • Short KD, Rajkumar SV, Larson D, . Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma. Leukemia 2011;25:906–908.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.